Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Larcombe-Young

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Expert Opinion on Biological Therapy|June 23, 2020
PanErbB-targeted CAR T-cell immunotherapy of head and neck cancerDaniel Larcombe-Young, Sophie Papa, John Maher
STAR Protocols|May 27, 2022
Generation of human parallel chimeric antigen receptor (pCAR) T cells to achieve synergistic T cell co-stimulationDaniel Larcombe-Young, Lynsey Whilding, David Marc Davies, et al.
Immunotherapy Advances|June 27, 2025
GLUT5 armouring enhances adoptive T-cell therapy anti-tumour activity under glucose-limiting conditionsRobert Page, Olivier Martinez, Daniel Larcombe-Young, et al.
Biology|March 27, 2024
Engineering a Dual Specificity γδ T-Cell Receptor for Cancer ImmunotherapyDavid M Davies, Giuseppe Pugliese, Ana C Parente Pereira, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 15, 2024
Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent mannerCaroline M Hull, Daniel Larcombe-Young, Roberta Mazza, et al.
Clinical and Experimental Immunology|May 27, 2026
Optimisation of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validationFahima Kausar, Christopher Davis, Daniel Larcombe-Young, et al.
Frontiers in Immunology|February 28, 2022
Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-StimulationLeena Halim, Kushal K Das, Daniel Larcombe-Young, et al.
Cell Reports. Medicine|May 5, 2021
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumorsParis Kosti, James W Opzoomer, Karen I Larios-Martinez, et al.
Scientific Reports|June 3, 2020
Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)Ricarda M Hoffmann, Silvia Mele, Anthony Cheung, et al.
Cell Reports. Medicine|November 20, 2024
Solid tumor immunotherapy using NKG2D-based adaptor CAR T cellsJana Obajdin, Daniel Larcombe-Young, Maya Glover, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Expert Opinion on Biological Therapy|June 23, 2020
PanErbB-targeted CAR T-cell immunotherapy of head and neck cancerDaniel Larcombe-Young, Sophie Papa, John Maher
STAR Protocols|May 27, 2022
Generation of human parallel chimeric antigen receptor (pCAR) T cells to achieve synergistic T cell co-stimulationDaniel Larcombe-Young, Lynsey Whilding, David Marc Davies, et al.
Immunotherapy Advances|June 27, 2025
GLUT5 armouring enhances adoptive T-cell therapy anti-tumour activity under glucose-limiting conditionsRobert Page, Olivier Martinez, Daniel Larcombe-Young, et al.
Biology|March 27, 2024
Engineering a Dual Specificity γδ T-Cell Receptor for Cancer ImmunotherapyDavid M Davies, Giuseppe Pugliese, Ana C Parente Pereira, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 15, 2024
Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent mannerCaroline M Hull, Daniel Larcombe-Young, Roberta Mazza, et al.
Clinical and Experimental Immunology|May 27, 2026
Optimisation of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validationFahima Kausar, Christopher Davis, Daniel Larcombe-Young, et al.
Frontiers in Immunology|February 28, 2022
Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-StimulationLeena Halim, Kushal K Das, Daniel Larcombe-Young, et al.
Cell Reports. Medicine|May 5, 2021
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumorsParis Kosti, James W Opzoomer, Karen I Larios-Martinez, et al.
Scientific Reports|June 3, 2020
Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)Ricarda M Hoffmann, Silvia Mele, Anthony Cheung, et al.
Cell Reports. Medicine|November 20, 2024
Solid tumor immunotherapy using NKG2D-based adaptor CAR T cellsJana Obajdin, Daniel Larcombe-Young, Maya Glover, et al.
Pageof 2